Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Antithrombotic Treatments Between Aspirin and Warfarin After Bioprosthetic Heart Valve Replacement
KCT0011353Phase 4
Key facts
- Status
- Recruiting
- Start
- Jun 2026
- Countries
- 1
- Sponsor
- Edwards Lifesciences
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Conditions
- aortic valve disease (AVD)mitral valve disease
01
Overview
Phase 4, randomised trial in aortic valve disease (AVD) and mitral valve disease comparing Aspirin arm with Warfarin arm (2 arms). Started Jun 2026; status: recruiting.
02
Design
2 arms- Study design
- Randomized
Aspirin arm
Participants receive aspirin as antithrombotic therapy for 6 months after bioprosthetic heart valve replacement.
Warfarin arm
Participants receive warfarin as antithrombotic therapy for 6 months after bioprosthetic heart valve replacement.
03
Who it enrols
Adult patients in Korea undergoing bioprosthetic aortic or mitral valve replacement surgery and requiring postoperative antithrombotic therapy.
Beyond the preview
Go deeper on KCT0011353.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011353.